SPH3127

Add links
Source: Wikipedia, the free encyclopedia.
SPH3127
Legal status
Legal status
  • Investigational
Identifiers
  • Methyl N-[3-[3-[(1R)-1-[cyclopropyl-[(2R)-morpholine-2-carbonyl]amino]ethyl]-6-methylpyrazolo[3,4-b]pyridin-1-yl]propyl]carbamate
JSmol)
  • CC1=NC2=C(C=C1)C(=NN2CCCNC(=O)OC)[C@@H](C)N(C3CC3)C(=O)[C@H]4CNCCO4
  • InChI=1S/C22H32N6O4/c1-14-5-8-17-19(26-27(20(17)25-14)11-4-9-24-22(30)31-3)15(2)28(16-6-7-16)21(29)18-13-23-10-12-32-18/h5,8,15-16,18,23H,4,6-7,9-13H2,1-3H3,(H,24,30)/t15-,18-/m1/s1
  • Key:GRTDDIZIUSADLD-CRAIPNDOSA-N

SPH3127 is a small-molecule renin inhibitor developed by Shanghai Pharmaceuticals for hypertension and kidney disease. It is believed to be more potent than aliskiren.[1][2][3]

References

  1. S2CID 251400126
    .
  2. S2CID 201848935
    .
  3. S2CID 232104329
    .
Retrieved from "https://en.wikipedia.org/w/index.php?title=SPH3127&oldid=1192904135"